The purpose of the study is to investigate the effect of ceftobiprole treatment on intestinal microflora in healthy volunteers.
This is an open-label, single center study to investigate the effect on human intestinal microflora of multiple doses of ceftobiprole treatment administered at 8 hours intervals for 7 consecutive days. Careful investigation of the effect of Ceftobiprole treatment on the intestinal microflora is of importance since alteration of the intestinal microflora balance may facilitate colonization by pathogenic bacteria strains or enable microorganisms already present in the normal microflora to develop resistance. A total of 7 fecal samples will be collected on day 2, 4, 7, 10, 14 and 21 for determination of ceftobiprole concentration in fecal, intestinal microflora pattern and measuring the susceptibility for Ceftobiprole of isolated bacterial strains. A total of 13 plasma samples will be collected on day 1, 4, 7, 10, 14 and 21 for determination of ceftobiprole concentration in plasma. Safety evaluations including physical examination, vital signs, clinical laboratory tests, electrocardiogram and adverse event monitoring will be performed throughout the study. 500 mg ceftobiprole, intravenous infusion over 120 minutes, every 8 hours for 7 consecutive days
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
Bacterial strains and numbers in feces; Minimum inhibitory concentrations for ceftobiprole for isolated resistant strains
Time frame: Day 2, 4, 7, 10, 14 and 21
Fecal concentration of ceftobiprole
Time frame: Day 2, 4, 7, 10, 14 and 21
Plasma Concentration of ceftobiprole
Time frame: Day 1, 4, 7, 10, 14, and 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.